Cargando…

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea

SIMPLE SUMMARY: TERT promoter mutation has recently emerged as a promising prognostic biomarker for aggressive papillary thyroid cancer (PTC), along with BRAF B600E mutation. The prevalence of the TERT promoter mutations has been reported as relatively uncommon in Asian countries. We report on a pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Min Jhi, Kim, Jin Kyong, Kim, Gi Jeong, Kang, Sang-Wook, Lee, Jandee, Jeong, Jong Ju, Chung, Woong Youn, Kim, Daham, Nam, Kee-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563418/ https://www.ncbi.nlm.nih.gov/pubmed/36230856 http://dx.doi.org/10.3390/cancers14194928

Ejemplares similares

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
por: Ban, Eun Jeong, et al.
Publicado: (2021)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Dynamic risk stratification in medullary thyroid carcinoma: Single institution experiences
por: Choi, Jung Bum, et al.
Publicado: (2018)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Vitamin D Receptor Expression and its Clinical Significance in Papillary Thyroid Cancer
por: Kim, Min Jhi, et al.
Publicado: (2022)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer
por: Lee, Seul Gi, et al.
Publicado: (2016)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAF(V600E) mutations in papillary thyroid carcinoma
por: Yoon, Jung Hyun, et al.
Publicado: (2020)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Current trends in the features of male thyroid cancer: Retrospective evaluation of their prognostic value
por: Kim, Min Jhi, et al.
Publicado: (2019)

Completion Total Thyroidectomy Is Not Necessary for Papillary Thyroid Microcarcinoma with Occult Central Lymph Node Metastasis: A Long-Term Serial Follow-Up
por: Choi, Soon Min, et al.
Publicado: (2020)

Surgical outcomes of laparoscopic adrenalectomy for primary hyperaldosteronism: 20 years of experience in a single institution
por: Kim, Kwangsoon, et al.
Publicado: (2019)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

Medullary thyroid carcinoma: a 30-year experience at one institution in Korea
por: Lee, Cho Rok, et al.
Publicado: (2016)

Clinical Assessment of Pediatric Patients with Differentiated Thyroid Carcinoma: A 30-Year Experience at a Single Institution
por: Kim, Kwangsoon, et al.
Publicado: (2020)

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
por: Lee, Seong Jin, et al.
Publicado: (2011)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma
por: Kim, Kwangsoon, et al.
Publicado: (2018)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Is familial papillary thyroid microcarcinoma more aggressive than sporadic form?
por: Lee, Cho Rok, et al.
Publicado: (2017)

Comparison of Surgical Outcomes between Robotic Transaxillary and Conventional Open Thyroidectomy in Pediatric Thyroid Cancer
por: Lee, In A, et al.
Publicado: (2021)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

Whole Exome Sequencing Identifies a Novel Hedgehog-Interacting Protein G516R Mutation in Locally Advanced Papillary Thyroid Cancer
por: Lee, Woo Kyung, et al.
Publicado: (2018)

A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation
por: Kim, Wook Youn, et al.
Publicado: (2013)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system
por: Kim, Kwangsoon, et al.
Publicado: (2020)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience
por: Kure, Shoko, et al.
Publicado: (2019)

The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades
por: Hong, A Ram, et al.
Publicado: (2014)

Clinical Value of Lymph Node Ratio Integration with the 8(th) Edition of the UICC TNM Classification and 2015 ATA Risk Stratification Systems for Recurrence Prediction in Papillary Thyroid Cancer
por: Lee, Jandee, et al.
Publicado: (2019)

Clinical Implications of Age in Differentiated Thyroid Cancer: Comparison of Clinical Outcomes between Children and Young Adults
por: Kim, Kwangsoon, et al.
Publicado: (2022)

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry
por: Estrada-Flórez, Ana P, et al.
Publicado: (2019)

Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
por: Ren, Haoyu, et al.
Publicado: (2018)

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
por: Paek, Se Hyun, et al.
Publicado: (2017)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_iiv3a28t78eb6gjskj3illupan